Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-22-006669
Filing Date
2022-05-02
Accepted
2022-05-02 17:15:42
Documents
15
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A apre-20211231x10ka.htm   iXBRL 10-K/A 521593
2 EX-31.3 apre-20211231xex31d3.htm EX-31.3 7295
3 EX-31.4 apre-20211231xex31d4.htm EX-31.4 8367
  Complete submission text file 0001558370-22-006669.txt   805359

Data Files

Seq Description Document Type Size
4 EX-101.SCH apre-20211231.xsd EX-101.SCH 4251
5 EX-101.DEF apre-20211231_def.xml EX-101.DEF 20469
6 EX-101.LAB apre-20211231_lab.xml EX-101.LAB 27391
7 EX-101.PRE apre-20211231_pre.xml EX-101.PRE 16828
9 EXTRACTED XBRL INSTANCE DOCUMENT apre-20211231x10ka_htm.xml XML 10436
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39069 | Film No.: 22883234
SIC: 2834 Pharmaceutical Preparations